Albuminuria News and Research RSS Feed - Albuminuria News and Research

Albuminuria also called proteinuria or urine albumin—is a condition in which urine contains an abnormal amount of protein. Albumin is the main protein in the blood. Proteins are the building blocks for all body parts, including muscles, bones, hair, and nails. Proteins in the blood also perform a number of important functions. They protect the body from infection, help blood clot, and keep the right amount of fluid circulating throughout the body.
Majority of young adults with abdominal obesity unaware of CKD risk

Majority of young adults with abdominal obesity unaware of CKD risk

Many young adults with abdominal obesity exhibit a readily detectable risk factor for chronic kidney disease (CKD), yet the vast majority don't know they're at risk, according to a study of nationwide health data led by Albert Einstein College of Medicine researchers that was published online today in the journal PLOS ONE. [More]
Sickle cell disease treatment may help protect kidney function in patients

Sickle cell disease treatment may help protect kidney function in patients

A drug used to treat sickle cell disease may provide an added benefit of protecting patients' kidney function, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. [More]
Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Among patients with diabetes and kidney disease, most receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, the addition of the medication finerenone compared with placebo resulted in improvement in albuminuria (the presence of excessive protein [chiefly albumin] in the urine), according to a study in the September 1 issue of JAMA. [More]
Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

The Lancet Diabetes & Endocrinology is pleased to announce that the following paper will be published to coincide with presentation at the 52nd ERA-EDTA Congress, taking place in London, UK, May 28 - 31, 2015. [More]
Measuring kidney function and damage may help predict people at risk for heart disease

Measuring kidney function and damage may help predict people at risk for heart disease

Simple measures of kidney function and damage may be just as good at predicting who is at risk for heart failure and death from heart attack and stroke as traditional tests of cholesterol levels and blood pressure, new Johns Hopkins Bloomberg School of Public Health-led research suggests. [More]
First European approval of drug to treat genetic kidney disease ADPKD

First European approval of drug to treat genetic kidney disease ADPKD

Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease [More]
New Johns Hopkins-led research suggests risk factors for developing acute kidney injury

New Johns Hopkins-led research suggests risk factors for developing acute kidney injury

Physicians treating hospitalized patients for conditions unrelated to the kidneys should pay close attention to common blood and urine tests for kidney function in order to prevent incidental injury to the organs that help cleanse the body of toxins, new Johns Hopkins Bloomberg School of Public Health-led research suggests. [More]
Blood pressure-lowering treatment lowers CVD, heart disease risks among type 2 diabetes patients

Blood pressure-lowering treatment lowers CVD, heart disease risks among type 2 diabetes patients

Blood pressure-lowering treatment among patients with type 2 diabetes is associated with a lower risk of cardiovascular disease (CVD) and heart disease events and improved mortality, according to a study in the February 10 issue of JAMA. [More]
Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). [More]
Albuminuria change is a strong cardiovascular risk indicator in diabetes

Albuminuria change is a strong cardiovascular risk indicator in diabetes

Changes in albuminuria predict cardiovascular mortality and morbidity over and above glucose levels and blood pressure, say researchers. [More]
Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg. [More]
New research uncovers abnormal molecular signaling pathways for kidney failure

New research uncovers abnormal molecular signaling pathways for kidney failure

Prevention and reversal of chronic kidney disease is an urgent public health need. The disease affects 1 in 10 Americans, is debilitating and deadly, and existing drugs, at best, offer only mild delay in progression to end-stage kidney failure. [More]
New study examines factors that may lead to end stage renal disease

New study examines factors that may lead to end stage renal disease

About 33 percent of people with type 2 diabetes suffer kidney damage that progresses to end stage renal disease, at which point they require either dialysis or kidney transplantation. Scientists have thought that this kidney disease is driven by damage to the glomeruli, blood vessels in the kidney, which spill the protein albumin into the urine. Current treatments targeting the resulting "albuminuria" do not prevent kidney failure. [More]
NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013. [More]
First Nations adults with diabetes more likely to face risk of end-stage kidney disease

First Nations adults with diabetes more likely to face risk of end-stage kidney disease

First Nations adults with diabetes have more than double the risk of end-stage kidney disease compared with non-First Nations adults, found a new study in CMAJ (Canadian Medical Association Journal). [More]
New evidence shows particulate matter exposure associated with kidney damage

New evidence shows particulate matter exposure associated with kidney damage

Many first responders working at Ground Zero following the 9/11 tragedy were exposed to cement dust, smoke, glass fibers, and heavy metals. Exposure to high levels of such particulate matter caused significant damage to first responders' kidneys, according to research presented at ASN Kidney Week 2013 November 9 at the Georgia World Congress Center in Atlanta, GA. [More]
Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the initiation of a multinational Phase II clinical study of GKT137831 in patients with diabetic nephropathy. [More]
Urinary protein may be early warning sign regarding patients' cognitive abilities

Urinary protein may be early warning sign regarding patients' cognitive abilities

The presence of protein in the urine may be a marker of risk for future cognitive decline in patients with type 2 diabetes and normal kidney function, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). [More]
High levels of urinary albumin-to-creatinine ratio linked with greater risk of CHD in black individuals

High levels of urinary albumin-to-creatinine ratio linked with greater risk of CHD in black individuals

In a large national study, higher levels of the urinary albumin-to-creatinine ratio was associated with greater risk of incident but not recurrent coronary heart disease in black individuals when compared with white individuals, according to a study in the August 21 issue of JAMA. [More]
NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease. [More]
Advertisement
Advertisement